Mycobacterium tuberculosis (MTB) infects one third of the world's population and continues to be a leading cause of death. Although immune responses by immunocompetent individuals can contain infection, sterilizing immunity is not usually achieved 1 . Infected individuals harbor latent disease with the potential for future reactivation, clinical disease, infectious spread and mortality.
a r t i c l e s
Mycobacterium tuberculosis (MTB) infects one third of the world's population and continues to be a leading cause of death. Although immune responses by immunocompetent individuals can contain infection, sterilizing immunity is not usually achieved 1 . Infected individuals harbor latent disease with the potential for future reactivation, clinical disease, infectious spread and mortality.
The hydrophobic cell envelope of MTB may be involved in several aspects of tuberculosis pathogenesis, including long-term survival in the host. MTB cell wall components stimulate host responses and contribute to the activity of Freund's adjuvant 2 . The mycobacterial cell wall contains glycolipids, which contribute to resistance to bactericidal free radicals 3 and modulate immune functions, including phagosome maturation 4, 5 and cytokine production. The cell wall also contains an abundance of N-terminally triacylated lipoproteins 6, 7 . Four small homologous lipoproteins (LprG, LprA, LppX and LprF), only found in the suborder of Corynebacterineae, contain a signal peptide for secretion through the Sec system and a lipobox motif for lipid modification on a conserved cysteine. Diacylglycerol is linked by a thioester bond to the cysteine, and a third acyl chain is attached by an amide bond to the amino group of the cysteine, resulting in triacylation. These lipoproteins are predicted to be localized to the periplasm or cell wall-for example, anchored to the outer leaflet of the cell membrane through their acyl chains. LprG (Rv1411c) may function with the other protein in its operon, a membrane pump (Rv1410c). Knockout of the LprG or its operon results in attenuated growth and survival in mice and macrophages [8] [9] [10] . Deletion of the LprG operon in Mycobacterium smegmatis results in decreased sliding motility and altered cell morphology 11 , suggesting that LprG function may be related to cell wall biosynthesis. LppX has also been proposed to be involved in cell wall biosynthesis by binding and transporting phthiocerol dimycocerosate (PDIM) 12 .
Toll-like receptor 2 (TLR2), which forms heterodimers with TLR1 or TLR6, is an important contributor to innate immune recognition of MTB [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . TLR2/TLR1 heterodimers bind triacylated lipopeptides. TLR2 agonist activity has been shown for the following MTB lipoproteins (MTB H37Rv gene nomenclature and protein name synonyms in parentheses): LpqH (Rv3763, 19-kD lipoprotein) [18] [19] [20] [21] , LprA (Rv1270c) 23 , LprG (Rv1411c, p27) 24 and Psts1 (Rv0934, PhoS1 or p38) 25 . Mycobacterial agonists of TLR2 also include glycolipids-for example, phosphatidyl-(myo)-inositol mannosides (PIMs), lipomannans (LMs), lipoarabinomannans (LAMs) and inositol phosphate-capped LAMs (PI-LAMs) 13, 14, 22 .
We investigated the structural basis of TLR2 agonist activity of MTB LprG. Crystal structures show that the thioether-linked diacylglycerol binds a hydrophobic pocket in TLR2, and the amide-linked third acyl chain binds TLR1 (ref. 26) . Unexpectedly, our studies show that nonacylated LprG (NA-LprG) retains TLR2 stimulatory capacity, and the crystal structure of NA-LprG reveals a glycolipid binding pocket lined with hydrophobic residues that could accommodate lipids with three acyl chains. This pocket noncovalently binds triacylated glycolipids, and the introduction of a single point mutation in this pocket blocks the glycolipid binding function of LprG. We propose that LprG functions in mycobacteria as a carrier of glycolipids during their trafficking and delivery to the mycobacterial cell wall, contributing to virulence 8, 11 and providing potential opportunities for targeting in drug design. In addition, the glycolipid carrier function of LprG may facilitate recognition of triacylated glycolipids by TLR2.
RESULTS

LprG carries a mycobacterial TLR2 agonist
In the prolipoprotein maturation pathway, N-terminal acylation of a cysteine results in a lipoprotein capable of inducing a potent TLR2 response. To determine the importance of N-terminal acylation to TLR2 agonist activity, we compared the TLR2 agonist activity of two homologous MTB lipoproteins, LprG and LprA, with and without N-terminal triacylation. These lipoproteins are predicted to be similarly acylated by a common enzymatic pathway 27 and, therefore, to have similar TLR2 activity, yet acylated LprG induced TLR2-dependent interleukin 8 (IL-8) secretion with more than ten-fold greater potency than acylated LprA in a bioassay with HEK 293 cells transfected to express TLR2 and CD14 (Fig. 1a) or TLR2 alone ( Supplementary  Fig. 1 ). Accordingly, we designed nonacylated forms with the signal peptide removed and the N-terminal cysteine replaced with methionine to investigate whether structures other than the acyl chains could affect TLR2 agonist activity. We expressed recombinant hexahistidinetagged acylated and nonacylated versions of MTB LprA and MTB LprG in M. smegmatis and assessed them for TLR2 agonist activity. Consistent with prior data 23 , NA-LprA lacked TLR2 activity, indicating that acylation of LprA was essential for its TLR2 activity (Fig. 1a) . In contrast, NA-LprG retained substantial TLR2 activity (Fig. 1a) , showing that LprG possesses a previously unknown determinant of TLR2 agonist activity independent of its N-terminal acylation.
NA-LprG had substantially reduced activity when expressed in Escherichia coli instead of M. smegmatis (Fig. 1b) , suggesting that LprG may carry TLR2 agonist(s) that are present in mycobacteria but not E. coli. Furthermore, TLR2 activity of NA-LprG purified from E. coli was substantially increased following incubation with a lysate of M. smegmatis (Fig. 1b) , MTB H37Ra (Fig. 1c) or MTB H37Rv (Fig. 1c) . In contrast, NA-LprA purified from E. coli did not acquire TLR2 activity from mycobacterial lysates (Fig. 1b,c) . These results show that NA-LprG binds a mycobacterial TLR2 agonist and can deliver it for recognition by TLR2.
LprG has a hydrophobic binding pocket for TLR2 agonists
We produced crystals for a truncation form of NA-LprG lacking N-terminal residues 1-35 (that is, the signal peptide and the triacylated cysteine) and C-terminal residues 232-236 (secondary-structure prediction indicated random coils for these sequences). This NA-LprG construct was a monomer in solution as determined by gel filtration (isolated as a single peak of ~22 kDa). We found the crystals to be in the C2 space group. We solved the structure using multiwavelength anomalous dispersion (MAD) methods and refined it to a resolution of 2.0 Å with two molecules in the asymmetry unit ( Table 1) . Both molecules (A and B) have large hydrophobic cavities with distinct entry portals.
The overall LprG structure consists of a single domain in an α/β fold with a β-sheet composed of 10 antiparallel strands on one side and 6 α-helices on the opposite side. Between the β-sheet and α-helices is a large cavity (~1,500 Å 3 ) (Fig. 2a) . The entrance to the cavity is approximately 9 Å × 20 Å and lies near β3, β4 and β5. The lower part of the molecule as positioned in Figure 2a is a twisted β-sheet (β6, β7, β8, β9 and β10) at the end of the cavity with a narrow binding channel (Fig. 2a,b) . In the central portion of the cavity, the β-sheet's concave face is toward the α-helices, forming the large cavity. The cavity and the portal are lined primarily with the side chains of hydrophobic residues (Fig. 2b) , which supports the hypothesis that LprG can bind lipids in the cavity.
Mutation of the pocket blocks association of TLR2 agonists
We designed a site-directed mutant of LprG in which we replaced Val91, located at the portal, with a bulkier tryptophan that was predicted to partially occlude the binding cavity (Fig. 3) . We expressed the mutant NA-LprG V91W in M. smegmatis and crystallized it. The overall r.m.s. deviation between wild-type NA-LprG and mutant NA-LprG V91W is ~1.0 Å, and the Luzzati coordination mean error is ~0.2 Å. The crystal structure of NA-LprG V91W shows that Trp91 shifted the portal wall inward by 3.5 Å compared to the wild type ( Fig. 3 and Table 1 ). The region between Leu73 and Leu76 was also shifted into the cavity by 0.5 Å to form van der Waals interactions with Trp91, further narrowing the portal. The loop between β3 and β4 and the loop between β5 and helix α2 were also relocated by ~2 Å from the entrance in response to the presence of the indole ring. Due to movement of these loops and the tryptophan mutation, the mutation reduced the size of the cavity entrance from 9 Å × 20 Å to 8 Å × 13 Å. The resulting cavity volume of NA-LprG V91W (1,200 Å 3 ) was substantially smaller than that of NA-LprG (1,500 Å 3 ). Thus, as predicted, the V91W mutation reduced the dimensions of the pocket entrance dimensions and the volume of the cavity.
The narrowed cavity entrance and smaller cavity of NA-LprG V91W were predicted to provide steric hindrance to limit substrate binding. Consistent with this hypothesis, NA-LprG V91W had substantially reduced TLR2 agonist activity relative to NA-LprG (Fig. 3) . Mutations at two other sites in the hydrophobic pocket (V194R and V217F) also decreased TLR2 agonist activity of NA-LprG (data not . Furthermore, when we expressed NA-LprG V91W in E. coli, purified it and then incubated it with a lysate of M. smegmatis or MTB, the V91W mutant lacked the ability to acquire TLR2 agonist activity from mycobacteria ( Fig. 3) . These results indicate that the hydrophobic cavity is a binding site for TLR2 agonist(s), which are delivered by LprG for recognition by TLR2.
Mycobacterial glycolipids are associated with LprG
We found NA-LprG to signal through TLR2-TLR1 heterodimers ( Supplementary Fig. 2 ), a pattern observed with mycobacterial glycolipids such as LAM 16 and LM 15 , as well as triacylated lipopeptide. To identify its associated TLR2 agonists, we purified NALprG from M. smegmatis by nickel-affinity and anion-exchange chromatography and subjected it to PAGE (Fig. 4) . Silver stain and anti-hexahistidine western blotting of NA-LprG, NA-LprG V91W or NA-LprA shows a single band at approximately 24 kDa ( Fig. 4a and data not shown). Staining of carbohydrates after periodate oxidation showed additional bands that comigrated with protein molecular weight markers of 25-35 kDa, 14-18 kDa and <10 kDa (Fig. 4b) , which correspond roughly to the expected positions of LAM, LM and PIM, respectively, and were found to comigrate with authentic glycolipid standards ( Fig. 4d and data not shown). These bands likely represent glycolipids because they were seen after periodate oxidation but not on conventional silver stain, and glycolipids in the PIM-LAM series resolve as broad bands based on heterogeneity of the arabinan and mannan components in each molecular species. Notably, LAM and LM were associated with NA-LprG but not NALprG V91W or LprA, indicating that these glycolipid agonists of TLR2 are associated preferentially with NA-LprG. We detected an association of PIM with NA-LprG, to a lesser degree with NA-LprA and only minimally with NA-LprG V91W. Western blotting with polyclonal anti-M. bovis BCG antibody revealed bands consistent with LAM, LM and PIM in association with NA-LprG but not NA-LprG V91W or NA-LprA ( Fig. 4c; anti-BCG staining may detect only a subset of PIM species). Furthermore, western blotting with a LAM-specific monoclonal antibody confirmed the association of LAM with NA-LprG and its absence from NA-LprG V91W and NA-LprA (Fig. 4d) .
LAM, LM, and PIM share a common structural core, suggesting that they all associate with NA-LprG via this shared structural motif, which may also contribute to TLR2 agonist activity. To determine the structures of small molecules associated with NA-LprG and related proteins, we used methanol to denature proteins and allow detection of protein-associated small molecules with mass to charge (m/z) ratio up to 2,000 by nESI-MS. Methanol alone (Fig. 4e) or methanol elutes of an unrelated protein, Pab C (Supplementary Fig. 3 ), did not 
give detectable ions. In contrast, NA-LprG expressed in M. smegmatis yielded ions corresponding to mycobacterial phospholipids ( Fig. 4e and Supplementary Fig. 3) . Ions detected at m/z 851.4, 1,013.5, 1,175.5 and 1,413.7 corresponded to the expected masses of diacyl phosphatidylinositol, diacyl phosphatidylinositol monomannoside (PIM 1 ), diacyl phosphatidylinositol dimannoside (PIM 2 ) and triacyl PIM 2 (Ac 1 PIM 2 ), respectively. CID-MS yielded product ions expected from these proposed structures, confirming assignments based on mass alone ( Fig. 4e and Supplementary  Fig. 3 ). Thus, LprG binds at least four structurally related molecules that all contain phosphatidylinositol as the core structure but differ in the number of mannose units and fatty acyl chains. We used LC-MS to compare mass spectral signals of individual molecular species eluted from the same molar quantity of NA-LprG, NA-LprG V91W or NA-LprA (Fig. 4f-i) . We used total ion current as a control to confirm comparable input of protein (Fig. 4f) , and we monitored signals simultaneously in narrow ranges (± 0.5 a.m.u.) near the expected masses of diacyl phosphatidylinositol (Fig. 4g) , diacyl PIM 1 (Fig. 4h) and Ac 1 PIM 2 (Fig. 4i) . Diacyl phosphatidylinositol and diacyl PIM 1 were associated with NA-LprG and NA-LprA but only in lower amounts with NA-LprG V91W. In contrast, triacylated Ac 1 PIM 2 was only associated with NA-LprG. Whereas LprA binds only diacylated PIMs, LprG binds both diacylated and triacylated PIMs. Because a large proportion of LAM is triacylated 28 , the preferential ability of LprG to bind triacylated PIMs likely explains the greater association of LAM with LprG relative to LprA.
There are no known differences between M. smegmatis and MTB with regard to structures of phosphatidylinositol and PIM species. Comparative mass spectral profiling of phospholipids isolated from whole bacteria revealed the following m/z values for abundant molecular species in MTB versus M. smegmatis, respectively: 851.564 versus 851.562 for phosphatidylinositol, 1,013.66 versus 1,013.64 for PIM 2 and 1,413.89 versus 1,413.89 for Ac 1 PIM 2 . These data reveal no substantial differences in structures of phosphatidylinositol or PIM species between M. smegmatis and MTB, suggesting that these glycolipids will similarly associate with LprG in both M. smegmatis and MTB (LprG was cloned from MTB for these studies).
Structure of Ac 1 PIM 2 bound to NA-LprG
To understand the structural basis of glycolipid binding, we incubated NA-LprG with an equimolar mixture of PIM and phosphatidylinositol from M. smegmatis. We solved the crystal structure of Ac 1 PIM 2 bound to NA-LprG to 1.85-Å resolution ( Fig. 5 and Table 1 ). The overall structure of the protein, the electrostatic surface of the complex and the cavity volume were similar to those of the apo protein (r.m.s. deviation of 0.6 Å and cavity volume of 1,500 Å 3 ). In the NA-LprG PIM crystal, one molecule (A) in the asymmetric unit has a triacylated Ac 1 PIM 2 bound, and the other molecule (B) has nothing bound. Although both protein molecules are very similar in structure (r.m.s. deviation of 1.3 Å), molecule B shows an ~2-Å movement for the α-helix-loop-α-helix motif at the portal to the Ac 1 PIM 2 binding site. The movement of this α-helix-loop-α-helix motif (Asp94-Gln106) repositions the side chain of Tyr102 ~3 Å, where it sterically prohibits . In addition to the V91W mutation, NA-LprG and NA-LprG V91W constructs used for crystallization included minor differences unrelated to the pocket structure (for example, NA-LprG V91W has a longer C-terminal coil). Otherwise, overall structures were similar with differences due to the V91W mutation localized to the cavity and entrance. The movement of β3, β4 and the loop between β3 and β4 affects cavity and entrance size. (Fig. 5a,c) . The interactions between LprG and Ac 1 PIM 2 were mainly through van der Waals contacts between the hydrophobic side chains within the cavity and the three acyl chains of the ligand. The deepest part of the cavity, where the mannosyl C16 chain is located, appears to be capable of accommodating an a r t i c l e s acyl chain that is at least two more carbons in length (Fig. 5a) . We found the sugar moieties of Ac 1 PIM 2 on the edge of the entry portal, directly outside the cavity. The α-helix-loop-α-helix region occupies about half of the LprG cavity entrance, very close to where mannosyl inositol binds in molecule A. This region is negatively charged (Fig. 5d) , providing a favorable environment for sugar binding. However, in the structure of NA-LprG PIM, we observed only two relatively weak interactions between the sugar moieties of Ac 1 PIM 2 . They are hydrogen bonds between the backbone oxygen of Gly42 and the 4-hydroxy of C16 acyl mannose (~2.7 Å) and between the backbone oxygen of Asp100 and the phosphate oxygen of the ligand (~3.0 Å). Therefore, the major component of ligand recognition involves the hydrophobic residues in the cavity. Superimposed structures of the NA-LprG V91W mutant and NA-LprG PIM reveal that Trp91 overlaps with the C19 acyl chain at the sn1 position of Ac 1 PIM 2 (Fig. 5b) . Thus, the V91W mutation would occlude binding of Ac 1 PIM 2 , correlating with decreased association of Ac 1 PIM 2 from MS (Figs. 4 and 5) and decreased TLR2 activity (Fig. 3) .
LprG binds mycobacterial glycolipids that are TLR2 agonists
To directly test the ability of NA-LprG to bind mycobacterial glycolipids, we purified NA-LprG from E. coli (with little or no TLR2 activity), incubated it with LM or LAM, repurified it by nickel-affinity and anion-exchange chromatography and tested it for TLR2 agonist activity. NA-LprG was able to bind LM and LAM and deliver them for recognition by TLR2 (Fig. 6a,b) , but NA-LprG V91W (Fig. 6a,b) and NA-LprA (data not shown) lacked this ability, consistent with the pattern of LM and LAM association in Figure 4 . Notably, association with NA-LprG enhanced the apparent potency of LAM and LM by at least 1.5 log orders of magnitude (Fig. 6a,b) . This comparison is based on the molar concentrations of NA-LprG shown in Figure 6 , assuming that 100% of the NA-LprG molecules were loaded with LM or LAM. In the likelihood that glycolipid loading was less than 100% efficient, the factor by which association with NA-LprG enhanced glycolipid potency would be higher. We conclude that NA-LprG binds mycobacterial glycolipids and substantially enhances their recognition by TLR2.
Glycolipids contribute to the TLR2 activity of acylated LprG
Our studies indicate existence of two distinct determinants of TLR2 agonist activity of LprG: N-terminal acylation and chaperoned glycolipids. We studied acylated LprG and acylated LprG V91W to determine the relative contribution of these mechanisms. Acylated LprG V91W was more than a factor of 10 less potent than acylated LprG (Fig. 6c) , indicating that the majority of TLR2 agonist activity of acylated LprG was attributable to carried glycolipid. Consistent with this finding, Western blot analysis revealed association of LAM with acylated LprG (Supplementary Fig. 4 ). Acylated LprG V91W had potency similar to that of acylated LprA (Fig. 6c) , indicating that TLR2 activity remaining when glycolipids were not associated with LprG was similar to that of LprA, reflecting similar N-terminal acylation of these molecules. Thus, the higher potency of LprG relative to LprA results from LprG-associated glycolipids, which are a major determinant of the overall LprG TLR2 activity.
DISCUSSION
The discovery of a glycolipid carrier function has significant implications for the function of LprG in bacterial physiology. LprG is widely present in mycobacteria with 100% sequence identity among MTB complex species. LprG (Rv1411c) and p55 (Rv1410c) are encoded in an operon that is important for virulence 8, 11, 29 . We propose that LprG serves as a carrier to facilitate the assembly or trafficking of glycolipids. The LprG pocket structure confers specificity for binding triacylated lipids, which are a relatively small pool within the much larger pool of diacylated lipids. Glycolipids have important roles in bacterial physiology and host-pathogen interactions, and a potential future goal is the inhibition of these processes by targeting the pocket of LprG with chemotherapeutics.
LprG has a pocket that accommodates three acyl chains, raising the possibility that LprG, like LolA and LolB of Escherichia coli, may bind lipopeptides via their triacylated N termini. LolA and LolB, however, show less than 20% identity to LprG, and their lipid binding cavities are considerably smaller than LprG's. Furthermore, MS did not reveal other lipopeptides associated with LprG purified from M. smegmatis, possibly due to competition by glycolipid ligands in mycobacteria or potential structural constraints. It is also unlikely that LprG would bind its own acyl peptide without considerable unfolding as the N-terminal side of LprG is ~50 Å away from the binding cavity entrance. These considerations fit with functional data (Fig. 6c) and biochemical data ( Supplementary Fig. 4 ) that show glycolipid association with both NA-LprG and acylated LprG.
NA-LprG is unique among the studied proteins in its ability to bind Ac 1 PIM 2 , LM and LAM (Fig. 4) , all of which may contain the triacylated PIM core structure that fits within the LprG pocket (Fig. 5) . LAM is a complex polymer with a high molecular weight that cannot be analyzed by the MS systems reported here, but other studies show that a large proportion of naturally occurring LAM is triacylated 28 . Therefore, the preferential association of LAM with NA-LprG as compared to NA-LprA or NA-LprG V91W may be explained by acyl chain interactions with the pocket, as seen in the NA-LprG Ac 1 PIM 2 crystal structure. These findings are consistent with the observed TLR2/TLR1 dependence of signaling by MTB glycolipids in the PIM-LM-LAM series [14] [15] [16] [17] and the concept that TLR2 activity of these mycobacterial glycolipids requires their triacylation 30 . Figure 6 LprG binds purified mycobacterial glycolipids and facilitates their recognition by TLR2. (a,b) NA-LprG was purified from E. coli, incubated with LAM or LM from M. smegmatis, repurified and assessed for TLR2 activity using bone marrow-derived macrophages. TNF-α production was quantified by ELISA. LAM:NA-LprG, NA-LprG that was incubated with LAM and repurified; NA-LprG unloaded, NA-LprG that was sham-loaded with buffer and repurified; Naked LAM, glycolipid in the absence of NA-LprG. Data are reported as mean ± s.d. of triplicate macrophage assays. (c) Acylated LprG, LprA and LprG V91W were purified from M. smegmatis and assessed for TLR2 agonist activity with HEK293.TLR2/CD14 as in Figure 1 . Data are reported as mean ± s.d. of triplicate HEK293.TLR2/CD14 assays. 
Recognition of PIM by LprG primarily involves interactions between the hydrophobic cavity of LprG and the three fatty acyl chains of the glycolipid (Fig. 5a,d) . We cannot exclude contributions of the longer carbohydrate chains of LM and LAM to LprG binding. Our MS data indicate that the structures of PIMs associated with LprG-for example, Ac 1 PIM 2 -are similar in MTB and M. smegmatis. LMs and LAMs are formed by additional glycosylation of PIMs. LAM is mannose capped in MTB, unlike M. smegmatis, and the resulting mannose-capped LAM has lower TLR2 potency than PI-LAM from M. smegmatis, but MTB LAM has substantial TLR2 agonist activity. Furthermore, the ability of MTB lysate to efficiently 'charge' LprG with TLR2 activity (Fig. 1c) indicates that MTB glycolipids are an effective source of LprG-chaperoned TLR2 agonist.
The binding pocket of TLR2 is hydrophobic with a volume of 1,800 Å3, close to that of the LprG binding pocket, but contains only two acyl chains of lipopeptides 26, 31 and glycolipids 31 , perhaps due to a restricted entrance. The third acyl chain of triacylated glycolipids may bind TLR1 (ref. 26 ). Thus, the triacyl structure that provides specificity for binding to LprG also determines the ability of MTB glycolipids to signal through TLR2/TLR1. Although LprA does not chaperone triacylated TLR2 agonists, modeling of LprA also reveals a hydrophobic pocket (Supplementary Fig. 5 ), and we observed an association of diacylated glycolipids with LprA. Another MTB lipoprotein, LppX, has a hydrophobic pocket 12 . Other mycobacterial lipoproteins may be carriers of hydrophobic ligands, some of which may be TLR2 agonists, and the potential contribution of chaperoned molecules to TLR2 activity of other lipoproteins should be considered.
Although the localizations of LprG and NA-LprG remain to be determined, acylated LprG is predicted to traffic to the outer surface of the mycobacterial cell membrane, where LM and LAM are assembled 32 . LprG may contribute to LAM assembly, trafficking and/or insertion into the cell wall. NA-LprG is predicted to be localized to the cytoplasm, as it lacks a signal peptide, and its loading with glycolipids may occur upon bacterial lysis. NA-LprG is a very useful tool to dissect the different components of LprG TLR2 activity, carried glycolipids and N-terminal acylation, but future studies of physiologic functions should focus on acylated LprG.
LprG may enhance TLR2 recognition of MTB by direct and/or indirect mechanisms. LprG may directly convey glycolipids to host receptors, for example, TLR2 or CD14. This mechanism implies release of LprG from MTB, either spontaneously or during phagosomal processing of MTB, which may allow LprG to reach TLR2 molecules that target to phagosomes. In addition, a role for LprG in the assembly, trafficking and cell-wall insertion of glycolipids indicates that LprG may affect the bioavailability of glycolipid TLR2 agonists.
Our results suggest that host cells can co-opt the carrier function of LprG to enhance TLR2 recognition of mycobacterial glycolipids. Association of glycolipids with NA-LprG increased their apparent potency by at least a factor of 1.5 log. To our knowledge, this is the first report of a pathogen-derived protein serving as a carrier for the delivery of hydrophobic agonists for innate immune recognition. For LPS, another hydrophobic TLR ligand, transfer to TLR4 is enhanced by host-expressed carriers, LPS-binding protein 33 and CD14 (ref. 34) . LprG may deliver glycolipids to TLR2 via delivery to CD14, which we observed to increase recognition of NA-LprG, presumably by enhancing glycolipid delivery to TLR2.
LprG influences progression of MTB infection in vivo, as genetic deletion of Rv1411c (encoding LprG) in MTB H37Rv reduces the virulence of MTB in C57BL/6 mouse pulmonary aerosol infection models (CFU burden decreases by a factor of 1,000 to 10,000 relative to wild-type MTB H37Rv or a strain in which the genetic deletion has been complemented; Banaei, N., personal communication). This establishes the importance of LprG to virulence, apparently by its contributions to MTB cell-wall assembly, delivery of glycolipids to TLR2 or both.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/.
Accession codes. Protein Data Bank: Coordinates and structure factors have been deposited under accession codes 3MHA (LprG-PIM), 3MH9 (LprG V91W) and 3MH8 (LprG). 
